Day: August 21, 2020

SHANGHAI, China, Aug. 21, 2020 (GLOBE NEWSWIRE) — Pinduoduo Inc. (“Pinduoduo” or the “Company”) (NASDAQ: PDD), an innovative and fast growing technology platform and one of the leading Chinese e-commerce players, today announced its unaudited financial results for the second quarter ended June 30, 2020.Second Quarter 2020 HighlightsGMV1 in the twelve-month period ended June 30, 2020 was RMB1,268.7 billion (US$2179.6 billion), an increase of 79% from RMB709.1 billion in the twelve-month period ended June 30, 2019. Total revenues in the quarter were RMB12,193.3 million (US$1,725.9 million), an increase of 67% from RMB7,290.0 million in the same quarter of 2019. Average monthly active users3 in the quarter were 568.8 million, an increase of 55% from 366.0 million in the same quarter of 2019. Active buyers4 in...

Please find the financial statement for Q1 2020/21 in the attachment:AttachmentCompany_announcement_FY 2020-21_1_Q1

Tulikivi Corporation                                          Half year financial report 1–6/2020: Net sales on the previous year’s level, operating profit improves21 August 2020 at 1 p.m.– The Tulikivi Group’s second-quarter net sales were EUR 7.4 million (EUR 7.5 million, Apr–Jun 2019) and EUR 13.1 million (EUR 13.3 million, Jan–Jun 2019) in the review period.– The Tulikivi Group’s operating profit for the second quarter was EUR 0.5 (0.3) million, and the operating profit for the review period was EUR 0.0 (-0.4) million.– The Tulikivi Group’s second-quarter profit before taxes was EUR 0.3 million (0.1 million) and EUR -0.4 (-0.8) million for the review period.– Net cash flow from operating activities was EUR 0.6 (0.5) million in the second quarter and EUR 0.7 (0.6) million in the review period.– Order...

Tulikivi Oyj                                              Puolivuosikatsaus 1-6/2020: Liikevaihto edellisen vuoden tasolla ja liiketulos parani21.8.2020 klo 13.00– Tulikivi-konsernin liikevaihto oli toisella vuosineljänneksellä 7,4 Me (7,5 Me 4-6/2019) ja liikevaihto oli katsauskaudella 13,1 Me (13,3 Me 1-6/2019).– Tulikivi-konsernin liiketulos oli toisella vuosineljänneksellä 0,5 (0,3) Me ja liiketulos oli katsauskaudella 0,0 (-0,4) Me.– Tulikivi-konsernin tulos ennen veroja oli toisella vuosineljänneksellä 0,3 (0,1) Me ja tulos ennen veroja oli katsauskaudella -0,4 (-0,8) Me.– Liiketoiminnan nettorahavirta oli toisella vuosineljänneksellä 0,6 (0,5) Me ja katsauskaudella 0,7 (0,6) Me.– Tilauskanta oli katsauskauden päättyessä 3,3 (3,6) Me.– Nordic Talc Oy perustettiin Suomussalmen talkkivarantojen...

VANCOUVER, British Columbia, Aug. 21, 2020 (GLOBE NEWSWIRE) — Affinor Growers Ltd. (“Affinor Growers”) (CSE:AFI, OTC:RSSFF, Frankfurt:1AF) is pleased to announce that it has closed its $0.03 per unit financing announced on August 10, 2020 for gross proceeds of $382,337.The Units consist of one common share and one common share purchase warrant giving the warrant holder the right to buy another common share for two years at $0.06 per common share. In the event that the Company’s common shares trade at a price on the Canadian Securities Exchange (or such other exchange on which the common shares may be traded at such time) of greater than $0.20 per share for a period of 20 consecutive trading days, the issuer may accelerate the expiry date of the warrants by giving notice to the holders thereof by way of a news release, and in such...

21 August 2020Seneca Growth Capital VCT PlcChange of Registered OfficeSeneca Growth Capital VCT Plc announces that, with effect from 20 August 2020, its Registered Office has been changed to:9 The ParksHaydockNewton-Le-WillowsMerseysideWA12 0JQAll other contact details remain unchanged.For further information, please contact:John Hustler, Seneca Growth Capital VCT Plc at john.hustler@btconnect.comRichard Manley, Seneca Growth Capital VCT Plc at Richard.Manley@senecapartners.co.uk

Regulatory engagement provides clear pathway through Phase 3 to support filing for marketing approvals in US and EuropeRegulatory agreement of using Lucentis® and Eylea® in combination with OPT-302 across two pivotal Phase 3 trials increases the potential multi-billion dollar market opportunityLucentis® and Eylea® had combined sales for retinal diseases of USD11.9BN in 2019 Company on-track to initiate Phase 3 trials in early 2021             MELBOURNE, Australia, Aug. 21, 2020 (GLOBE NEWSWIRE) — Opthea Limited (ASX:OPT), a clinical-stage biopharmaceutical company developing a novel therapy to treat highly prevalent and progressive retinal diseases, is pleased to announce today that it has successfully completed End-of-Phase 2 meetings with the U.S. Food and Drug Administration (FDA), and a Scientific Advice meeting with the European...